Enanta Pharmaceuticals Inc (ENTA) News

Never seen a company with such a promising program and yet selling way before current asset values.

Whoever dumping the shares day in and out arent doing it because of fundamentals. Imo

Added again, that’s it for me.
It is ridiculously cheap but already over allocated by fair bit.

Ready for partnership or buyout announcement now LOL.

And pls if the RSV is bad, just be very bad so they will just stop the program and focus on immunology.

Still will have significant upside but less so if that happens.

Good luck everyone

RSV season

Looks like Florida and Georgia are in full swing for RSV now. Texas also has a high rate of test positivity. Hopefully the adult HR study will complete enrollment soon.

https://www.cdc.gov/nrevss/php/dashboard/index.html

As a reminder the only adult HR data w zelicapavir is the terminated transplant study. very small N, but the effect on VL was stark with a -7 log decrease in the treatment arm versus -2 log in the placebo arm. On the clinical side 1 our of 4 on placebo developed lower respiratory tract infection versus 0 out of 5 on treatment.

https://clinicaltrials.gov/study/NCT04633187?term=edp-938&aggFilters=status:ter&rank=1&tab=results

For sure a fund or funds are selling out while we dont have enough buyers to step out


Got some more today. Dont see much risk buying here but i thought the same and loaded up at 11s

Painful

Looks like Clubber Lang made the right call for what is ahead for ENTA shareholders.

Yes back to pretty much all time low

Painful

Unbelievable. Down from 13 to 9 last month or so. Only news during the same period was the great challenge data. Feel like a repeat of year end last year indeed

Yes it can take time to get all the data together but this is a small 90 patient study with viral load as primary endpoint I would assume they have at least that top like data for some time. I would think a few weeks not months to scrub data and unlock database but perhaps someone more knowledgeable can chime in

While on vacation here in Maryland, noticed that ENTA has a new patent regarding prevention of coronavirus viruses. Might be the rationale for pre-market up-trades. Please check Enanta patents as of November 19.

Isnt it normal to tak at least 2 to 3 months to do data analysis etc before doing a presentation?

So they might be just not ready yet?

My dream case is a buyout so maybe they are just busy negotiating a deal so no CC and no data presentation yet

Expect an earnings report on Monday 25 Nov and a conference call in December to discuss RSVPEDS trial results et al. IMO ENTA mgt has been sitting on (good) results for several weeks now. I do not see the logic of sitting on bad results. I see a follow through of good results for zelicapavir in the PEDS population.

And the problem is volume is super light especially on a down day

So whoever selling is selling into an vaccum

Less than 50k shares so far

Just no buyers

I don’t get it either but stocks overshoot in both directions all the time amd enta has been out of favor a long time now

Not sure why so much sellers day in and day out even the shares are selling below net cash and less than half of cash plus royalty value

And short interest is up as well it seems

The bounce and uptrend will be awesome ;)

Yes I think management will follow the last quarter's playbook and release a PR w earnings, no call, and guide towards a call with data release (peds and/or immunology update). So while not having a call is generally bearish, in this case I just think they are not bothering to hold a call w analysts until there is something meaningful to discuss

Gotcha, so your guess is ENTA will not have an earnings call for the 4th quarter and end of year, but management will wait till the end of December and then have a call on the PEDS trial results? Thanks.

Seems to be heading back down now. Declining to hold a call will generally do that, but last quarter there were no unpleasant surprises so hopefully this time will be the same

Yes, I understood your post. Best wishes my friend. ENTA had a nice turnaround this am…

I'm not suggesting anyone trade on inside info. I'm just suggesting there is flexibility in when they release data, and 2025 options tend to be priced late December

They cannot trade on inside info… that’s the bottomline //..\\
The tea leaves say ENTA goes up from here.

Imagine they get themselvesn some cheaply priced options, then right after they release good data and get a nice buyout - would they get into insider trading trouble from SEC?

Do they even allow to grant themselves if they are negotiating a buyout deal?

I am sure they will meet all the guidance for data this quarter, but it is less likely to be next Monday if there is no call IMO (I was serious about waiting until end of the quarter for options - i mean if you were management and were sitting on good data why not? Reg FD gives you plenty of leeway)

lol…

I hope the Q release will say they are looking for strategic options for the company due to sluggish stock price

I thought they were going to announce a new program under immunology this year too, so was expecting a info packed call.

I don’t see a PR so probably safe to say no call w earnings next week. So following playbook from last quarter will probably hold a call w peds data figuring not much to discuss otherwise.
Management could try and wait for late q4 after options priced

are u trying to jinx it again? 😅

OMG! … is ENTA going to close green? Here’s a biotech w/ strong financials, a promising pipeline and a record of success… yet the market yawns. In horse racing, this is called an overlay.
I believe Enanta is going to be ‘gobbled up’… 🦃🦃🦃

Oversold is an understatement here. Volume has been low. Seems liquidity just got sucked into all those Trump trades, and not enough buyers to counter the RFK induced biotech drawdown.

Pretty much back to flat YTD.

This is my new "pinned" tweet:
https://twitter.com/DewDiligence/status/1857569844218167375

Interesting…
https://creators.spotify.com/pod/show/rfkjr/episodes/Doctors-Discuss-Respiratory-Syncytial-Virus-e1r1cd2

Jake is a bitter person who lost money on ENTA and let that bitterness consume him.

all shorts are right so far

I think even the shorts could not have thought ENTA will trade so much lower than current asset values - I understand that it's not unsual for biotech to trade below, but it's rare we see names trading so much below the mark, especially with seeminly viable programs.

Added today and all my buys are now offically underwater as of today's close.

I had the same question earlier too... it's surprising that ENTA struggles with partnerships, especially since, at least from a layman perspective, their drug doesn't seem bad at all.

Maybe a timing thing... or maybe ENTA overestimated their leverage and missed opportunities because they were too comfortable with their cash position?? Perhaps they were overly confident that someone would eventually meet their asking price, only to end up with nothing.

Will see how the RSV goes.

dude (or dudette) I was joking
yeah he was right about the covid asset
all shorts are right so far

I would agree if it is under $ENTA, but would be an valuable asset for some who has better resources.

The inability to find a partner for over a year suggests they can't even give it away, so I am not sure about that but I would be happy to be wrong
By that thinking the hep b drug and nash/mash drugs could have value to a company like GSK that is active in those areas as an add on, but it is pretty much acknowledged that those assets have little to no value
now there could be unforeseen things that arise. If there is a paxlovid resistant mutant that becomes prevalent, and enta's drug retains activity (same MOA but there is non-overlapping resistance often still) then it could suddenly be worth a ton. Kind of like remdisivir suddenly found life after covid. but these are pie in the sky scenarios

Add COVID program to the below prognostication.

Jake2234

Re: biotech_researcher post# 2728

Monday, October 09, 2023 7:16:52 AM

Post#
2739
of 3457
What DD and other fail to recognize is repeated years of failures in the clinic with HBV and NASH programs. Investors have apparently lost all trust. The attempt to market these dead programs as for partnership is a complete joke!

Who is Jake

Jake Wins! You do not have to respond, you just conceded.

I put no value right now in enta Covid drug personally

I would agree if it is under $ENTA, but would be an valuable asset for some who has better resources.

But at current stock price, share price would double if assign zero value to everything else except cash + 45% royalty.

It's odd.

I put no value right now in enta Covid drug personally

Agreed. That ship has sailed.

I added more shares today at $9.7538.

I thought about it but bought a bit more VKTX at $50 even.

We don’t know symptom data but enta didn’t have a virologic signal unless you looked post hoc like baseline VL over 5.0, N negative etc
PFE also has the resources it doesn’t mean it was a good decision by them. They are now in a race with Shionogi who has a next gen PI with good DDI profile as well (beyond ensitrelvir)
I put no value right now in enta Covid drug personally

So why Ibuzatrelvir would go P3 but EDP-235 is having such difficulty finding regulatory pathway to P3?

I would venture it is about the money needed to run a big phase 3 trial. PFE has got it, ENTA doesn't so needs a partner.

Post-Hoc: RFK vs. Vivek, and the future of US drug policy> By Drew Armstrong

President-elect Donald Trump has just set up a showdown for the future of biopharma policy during his administration.

On one side is Trump’s pick to lead the Department of Health and Human Services, Robert F. Kennedy Jr. Kennedy is an anti-vaccine advocate who, at various points, has called for limiting drug ads, ending some government research on pharma treatments, and a re-review of data supporting vaccine safety. He has called the relationship between the FDA and industry corrupt, and has said that Americans take too many drugs for too little benefit.

On the other side is Vivek Ramaswamy, Trump’s pick to co-lead a new Department of Government Efficiency, charged with cutting red tape across government. Ramaswamy, a pro-business libertarian, is the founder of Roivant Sciences, the source of his significant wealth.

In stark contrast to Kennedy, Ramaswamy has called for less stringent reviews of drugs and faster approvals. On Friday in a social media post, the former pharma CEO said his “#1 issue with FDA is that it erects unnecessary barriers to innovation (e.g. two replicate phase 3 studies instead of one, refusal to accept valid clinical results from other nations, etc.).”

The merits of Ramaswamy’s ideas aside (and the fact that in many cases, two Phase 3 trials aren’t used for approval), the two represent almost entirely different philosophies about the biopharma industry. Kennedy sees the industry as dangerous and corrupt, and in need of far greater oversight and restriction by the government. Ramaswamy appears to see the government as the problem, holding back an industry that should deal with far less interference. Those views aren’t compatible.

Ibuzatrelvir - So why Ibuzatrelvir would go P3 but EDP-235 is having such difficulty finding regulatory pathway to P3?

I added more shares today at $9.7538.

Same here. I never expected ENTA to drop back to this level, especially with all the significant news coming up in the next few weeks.

re PFE next gen PI for Covid

BTW here are links to pfizer's phase 2 data as well as ct.gov listing
note that the drug is BID while enta's QD, although for a 5 day course i don't think bid is that much of a disadvantage (but all things being equal you prescribe the QD over BID drug)
PFE did see elevated LFTs at the highest dose. ENTA had the one pt w elevated LFTs but I don't think PFE is going to be squeaky clean on that front either
PFE did have better virology it seems, but they restricted patients to certain baseline viral loads and the medial VL was a full log higher than ENTA.
anyway just for future reference if anyone is interested:

https://pfizermedical.pfizerpro.com/api/vc/en/medical/assets/0f98ccb4-08bb-46d6-abfe-3a89b62dc8fc/Ibuzatrelvir%20Phase%202b%20Study%20results-updated%20poster%20%281%29.pdf

https://clinicaltrials.gov/study/NCT06679140?term=PF-07817883&rank=8

In my prior post, I was refrrring to the examination of ENTA's RSV data (under an NDA) that PFE could conceivably be doing as a prelude to a buyout offer.

Thanks Dew. It seems we are on the same page.

no and having an RSV antiviral is highly complementary
Quad screens are very common now and if PFE has both an RSV antiviral and covid antiviral they will be able to treat two of the 3 pathogens on the screen (flu is the third)
There are plenty of other companies that would be interested in an RSV drug so whether they sell the asset or partner there should be plenty of interest if the data is strong